NF-kappaB inhibitors and uses thereof
    124.
    发明申请
    NF-kappaB inhibitors and uses thereof 有权
    NF-κB抑制剂及其用途

    公开(公告)号:US20050020586A1

    公开(公告)日:2005-01-27

    申请号:US10726411

    申请日:2003-12-03

    申请人: Jetze Tepe

    发明人: Jetze Tepe

    摘要: A new class of imidazolines as 4-position esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma, etc.), antibacterial agents, and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-kB as well as potent activity against the Gram (+) bacterium. The compositions are also useful for treating autoimmune diseases and for inhibiting rejection of organ and tissue transplants.

    摘要翻译: 描述了一类新的具有非常有效的抗炎和抗微生物活性的4-位酯的咪唑啉。 这些咪唑啉的合成包括适用于组合合成方法的多组分反应。 这两个关键特征的组合在治疗脓毒性休克以及许多其他炎症(关节炎和哮喘)和感染性疾病方面提供了有效的治疗药物。 描述了使用这种新型非甾体药物作为抗炎剂(用于治疗哮喘等),抗菌剂和防腐剂。 这些化合物也可用于治疗肿瘤(如癌症)。 咪唑啉是转录因子NF-kB的有效抑制剂以及对革兰氏阴性菌(+)细菌的有效活性。 所述组合物还可用于治疗自身免疫疾病和抑制器官和组织移植排斥反应。